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INTRODUCTION
Cholesteatoma is defined by a keratinizing squamous epitheli-
um in the middle ear cavities. Although cholesteatoma is a be-
nign disease, it can invade neighboring tissues and often recur 
even if surgical resection is considered to be complete. Choles-
teatoma is traditionally classified as either acquired, essentially 
due to a chronic otitis process, or congenital. Congenital choles-
teatoma are classically presented as a white mass behind an in-
tact tympanic membrane, typically in the anterosuperior quad-
rant (1). Although acquired and congenital cholesteatoma are 
histologically identical, they do not share the same etiopatho-
genesis.
  Congenital cholesteatoma is thought to occur due to second-
ary failure of normal involution of the epidermoid formation. 
This collection of stratified squamous epidermoid cells appears 
during fetal development (1). Many other mechanisms have also 
been proposed, such as metaplasic origins or a migration of epi-
thelial cells from the external auditory canal (2, 3).
Objectives. There is a classical distinction based on clinical criteria between acquired and congenital cholesteatomas. To de-
termine if these two types of lesions show different immunohistochemical features, we have studied the expression 
patterns of three distinctive galectins (animal lectins implied especially in cellular proliferation and apoptosis) in both 
types of cholesteatomas and compared it to their expression patterns in external auditory canal skin.
Methods. Our study is based on nine acquired and eight congenital cholesteatomas, obtained from children during ear sur-
gery. Six specimens of normal adult auditory meatal skin served as control. Specimens were analyzed by immunohis-
tochemistry using monoclonal antibodies with galectin-1 and galectin-3, and a polyclonal antibody with galectin-7.
Results. We did not observe any differences in the galectin distribution pattern between congenital and acquired pediatric 
cholesteatomas. Compared to the control group, cholesteatomas present some particular features. There was no ex-
pression of galectin-1 and a lower expression of galectin-3 in the epithelium. Furthermore, we observed a preferen-
tially nuclear distribution of galectin-7 in cholesteatomas, whereas it is essentially cytoplasmic in the control group. 
Conclusion. The data reported in this study suggest, on the basis of a lesser marked galectin-3 in cholesteatomas epithelium 
compared with an external auditory canal skin, that an immature keratinocytes population is at the origin of these le-
sions and that galectin-3 and galectin-7 play a part in the capacity as apoptosis modulators. Our study does not estab-
lish a difference in the galectin expressions of congenital and acquired cholesteatomas, but it constitutes however an 
additional argument in favor of the “undifferentiated” origin of keratinocytes in cholesteatomas. 
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  In the same way, the origin of acquired cholesteatoma remains 
under discussion. Among the various advanced theories, the most 
probable one considers the epithelial migration as the origin of 
the pathology. This migration can either start from the margins 
of a tympanic perforation, or from the retraction of the tympan-
ic membrane (4).
  The particularly aggressive behavior of cholesteatomas can be 
explained - at least partially - by disorders in growth regulation 
and cellular death of keratinocytes. The apoptosis of excessive 
keratinocytes is related to modifications of expression of various 
proteins, in particular the phosphoprotein p53 (5). Recurrent 
cholesteatomas can be distinguished from nonrecurrent on the 
basis of the quantity and the distribution from apoptotic cells. 
Among proteins implied in the regulation of this population of 
keratinocytes, galectine-3 seems to hold a particular role (6). 
  Galectins are members of an animal lectin family defined by 
shared consensus amino acid sequences and an affinity for ß-ga-
lactose-containing oligosaccharides. To date, 15 different galec-
tins have been identified. They are implied in varied biological 
phenomena such as embryonic development, immune response, 
cellular proliferation or apoptosis. They also play a similar role 
to that of adhesion molecules on intercellular interactions and 
extracellular matrix-cell interaction (7-12).
  Although, the expression of galectins has been observed in 
many normal and pathological tissues studies (including choles-
teatomas for galectin-1, -3, and -8) (6), no previous study has 
been interested in the expression of these proteins in congenital 
and acquired cholesteatoma compared to external auditory canal 
skin.
  Based on the observation that histologically similar tumors 
can present different immunohistochemical patterns (13), it seem-
ed to us interesting to study the immunohistochemical behavior 
of congenital and acquired cholesteatomas on the basis of their 
expressions of galetin-1, -3, and -7 and to compare it with the 
expression patterns of these galectins in external auditory canal 
skin.
MATERIALS AND METHODS
Histopathologic and clinical data
Eight congenital cholesteatomas (six males, two females, aver-
age age 7.8 years) and 9 acquired pediatric cholesteatomas (eight 
males, one female, average age 9.6 years) were obtained imme-
diately after middle ear surgery. In all cases, it was a first surgical 
cure of cholesteatoma. Six congenital cholesteatomas were ob-
tained from the ENT Department of the “Reine Fabiola Chil-
dren’s Hospital” (Brussels, Belgium). The others were obtained 
from the ENT Department of the “Erasmus University Hospi-
tal” (Brussels, Belgium) and all were subjected to the standard 
diagnosis routine in the Department of Pathology of this same 
hospital. All the congenital cholesteatomas exhibited a classical 
otomicroscopic aspect for this disease, i.e., a white mass behind 
an intact tympanic membrane. Specimens of normal adult audi-
tory meatal skin (n=6) obtained during autopsy served as con-
trols. All autopsies were performed within a 24 hours postmor-
tem delay to ensure a good preservation and staining of tissue 
antigens (14). 
  The specimens were immediately fixed in 4% formaldehyde 
and embedded in paraffin. Sections were cut at a thickness of 5 
µm and processed for H&E staining using routine protocols. This 
study was approved by the ethical committee of the Erasmus 
University Hospital (Ref P2010/069).
Immunohistochemistry 
The 5-μm-thick sections were subjected to standard immunohis-
tochemistry, as previously detailed (15-17). The immunohisto-
chemical expression was visualized by means of streptavidin-bi-
otin-peroxidase complex kit reagents (BioGenex, San Ramon, 
CA, USA) with diaminobenzidine/H2O2 as the chromogenic 
substrate. Finally, the sections were counterstained with haema-
toxylin. Galectin-1 and galectin-3 expression was evidenced by 
means of two specific monoclonal antibodies, respectively (No-
vocastra, Newcastle, UK; dilution 1:100). Galetin-7 was immu-
nolocalized in tissues with a polyclonal rabbit anti-human galec-
tin-7 antibody, as detailed elsewhere (15). Negative controls had 
the primary antibodies replaced by non-immune serum (Dako, 
Glostrup, Denmark).
Immunohistochemistry: evaluation
We performed a semi-quantitative (for galectin-1 and galectin-7) 
and quantitative (for galectin-3) evaluation. For each slide, the 
entire tissue was analyzed. Two independent observers conduct-
ed on blind-labeled sections the assessment of the immunohis-
tochemical staining of galectin-1 and -7. 
  The assessment of the immunohistochemical staining was con-
sidered as follows: 1) For galectin-1, according to the presence 
or the absence of staining within the stroma and/or the epitheli-
um; 2) For galectin-3, a quantitative analysis is accomplished by 
computer-aided microscopy (×200 magnification; Histolab, Al-
phelys, France). The two studied variables were the labeling in-
dex (LI) and the index of transmitted intensity. The LI refers to 
the percentage of tissue area specifically stained by a given his-
tochemical marker. The Index of transmitted intensity denotes 
staining intensity; 3) For galectin-7, the score was established af-
ter counting the number of labeled nuclei compared to all nu-
clei. The staining was considered nuclear if more than 10% of 
nuclei were labeled in the epithelium. 
Statistical analysis
Due to the restricted number of cases and the obviously similar 
immunohistochemical staining in both of the cholesteatomas 
groups, we decided to compare directly the cholesteatomas (ac-
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ing the statistical analysis of the galectin-3 data, the differences 
between independent groups of quantitative data were analyzed 
by the Mann-Whitney non-parametric test. Concerning galec-
tin-1 and -7 (two binary variables), Fisher’s exact test were used. 
All the statistical analyses were carried out using Statistica (Stat-
soft, Tulsa, OK, USA).
RESULTS
We did not observe any differences in the galectin distribution 
pattern between congenital and acquired pediatric cholesteato-
mas (Table 1).
  For galectin-1, a significant difference (P=0.00002, Fisher’s 
exact test) is observed between the cholesteatoma and the ex-
ternal auditory canal skin group. In fact, cholesteatoma’s epithe-
lium does not express galectin-1, unlike the external ear skin 
specimens. Each specimen from both groups presented a stro-
mal staining for galectin-1 (Fig. 1).
  For galectin-3, the LI (P=0.0033, Mann-Whitney non-parame-
tric test) as well as the index of transmitted intensity (P=0.0026) 
are significantly different between both groups (Fig. 2). Indeed, 
external auditory canal skin presented an intense and wider ga-
lectin-3 staining compared with acquired and congenital choles-
teatomas. The staining in the external auditory canal skin group 
was particularly intense at intercellular junctions (Fig. 3).
  For galectin-7, the cholesteatoma group (acquired and con-
genital) presented a predominant nuclear staining, while the con-
trol group presented a cytoplasmic predominant staining (Fig. 4). 
Moreover, the distribution of cells whose nucleus was positive 
was distributed heterogeneously, with some areas rich in label  ed 
nucleus. This however, was statistically relevant (P=0.00009, 
Table 1. Galectin-1, -3, and -7 distribution patterns in external auditory canal (EAC) skin, acquired and congenital cholesteatoma
EAC skin Acquired cholesteatoma Congenital cholesteatoma
Galectin-1 Staining in epithelium and stroma Absence of staining in the epithelium staining in stroma A  bsence of staining in the epithelium  
staining in stroma
Galectin-3 Intense staining in epithelium Mild to moderate staining in epithelium Mild to moderate staining in epithelium
Galectin-7 C  ytoplasmic staining in the  
epithelium
In  tense nuclear staining and moderate cytoplasmic  
staining in the epithelium
In  tense nuclear staining and moderate  
cytoplasmic staining in the epithelium
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Fig. 1. Morphological aspect of the immunohistochemical staining for galectin-1 (×400). (A) External auditory canal, (B) acquired cholesteato-
ma, (C) congenital cholesteatoma. st, ststroma; ep, epithelium. 
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Fig. 2. Labeling index (LI) and index of transmitted intensity for galectin-3 in the three histological groups.Vander Ghinst M et al.: Galectins Expressions in Pediatric Cholesteatomas     65
Fisher’s exact test).
DISCUSSION
The main result of this study is that acquired and congenital chol-
esteatomas exhibit the same galectin distribution patterns. The 
comparative analysis of the immunohistochemical behavior of 
these two forms of cholesteatomas is an interesting method to 
obtain information on their possible origins. Although a distinc-
tion between the two types of cholesteatomas could be recently 
established on the basis of difference in length of telomeres (18), 
there is currently no other evidence that these two groups of 
cholesteatomas show a difference in biological properties. For 
example, the cytokeratins expression does not differ according 
to whether the cholesteatoma is congenital or acquired (19). Our 
study reaches the same conclusion regarding the expressions of 
galetin-1, -3, and -7. 
Galectins and cholesteatomas 
If the presence of galetin-1 and -3 is already documented in skin 
and cholesteatomas (6, 20), no study has yet looked at galectins 
expression analysis in cholesteatomas in comparison with skin 
from the external auditory canal. Moreover, galectin-7 has never 
been studied in cholesteatoma. Galectin-1 is expressed in many 
cellular types and plays a role in varied biological phenomena, 
such as proliferation, apoptosis and cellular adhesion (7-9, 20). 
Contrary to what had been noted by Sheikhole  slam-Zadeh et 
al. (6), which had shown a marked presence of galectin-1 in cho-
lesteatoma epithelium, we have observed an absence of marking 
of galectin-1 within cholesteatoma epithelium. But their stro-
mas, as well as the epithelium and the stromas of external audi-
tory canal skin, expressed in galectin-1. These contradictory re-
sults are probably explained by a difference between the anti-
bodies used: we employed a monoclonal anti-galectin-1 anti-
body, whereas a polyclonal antibody was used in their experi-
ments. The monoclonal antibodies, resulting from a lymphocy-
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Fig. 3. Morphological aspect of the immunohistochemical staining for galectin-3 (×400). (A) External auditory canal, (B) acquired cholesteato-
ma, (C) congenital cholesteatoma. st, ststroma; ep, epithelium.
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Fig. 4. Morphological aspect of the immunohistochemical staining for galectin-7 (×400). (A) External auditory canal, (B) acquired cholesteato-
ma, (C) congenital cholesteatoma. st, ststroma; ep, epithelium.66    Clinical and Experimental Otorhinolaryngology   Vol. 5, No. 2: 62-67 , June 2012 
tary clone and thus directed against only one epitope, are more 
specific - but also often less sensitive than polyclonal ones (21). 
This difference between the two studies would thus result either 
from a lack of specificity of the polyclonal antibodies, or of a 
lack of sensitivity of the monoclonal ones.
  Although, we know that the expression of galectin-1 in the 
epidermal layer evolves during embryogenesis and carcinogene-
sis (22), it is difficult to clarify the role of galectin-1 in cholestea-
tomas. Indeed, as in cholesteatoma, the studies seem contradic-
tory concerning the presence of galectin-1 in epidermis (23, 24). 
  Our study shows that galectin-3 is less expressed, both on the 
level of the surface marked and on the level of the intensity of 
marking, in cholesteatoma epithelium compared with the exter-
nal auditory canal skin. It was recently shown that the expres-
sion of galectin-3 increased during keratinocytes differentiation 
(20). This observation pleads in favor of an “undifferentiated ori-
gin” of keratinocytes in cholesteatomas. In the same way, it was 
suggested, on the basis of expression of the retinoic acids recep-
tors in cholesteatomas that an immature keratinocyte population 
is at the origin of cholesteatoma lesions (25). Haake and Cooklis 
(26) noted an important apoptosis rate in fetal keratinocytes. 
Moreover, they have suggested that apoptosis was a borrowed 
way by keratinocytes when their differentiation were not com-
plete. An abnormally high rate of apoptosis also precisely char-
acterizes cholesteatomas (5). This information is interesting, as 
the galectine-3 is known for its anti-apoptotic effect (10), espe-
cially in keratinocytes (27). It is interesting to note also that in 
malignancies conditions, the levels of expression of galectin-3 
decreased as the levels of differentiation decreased (28). Fur-
thermore, the same galectin-3 pattern expression is found in pso-
riasis, another keratinocyte pathologic condition (24).
  We have observed a preferentially nuclear distribution of ga-
lectin-7 in cholesteatomas. Galectin-7 is known to display pro-
apoptotic effects: it has been shown to be one of the genes whose 
expression is induced in the early steps of p53-mediated apop-
tosis (29). As proposed by Kuwabara et al. (30), galectin-7 would 
present pro-apoptotic properties when localized intracellularly, 
and that these effects should be induced in the nucleus rather 
than in the cytoplasm. It is also interesting to note that the ex-
pression of galectin-7 in hypopharyngeal and laryngeal dyspla-
sia is characterized by a shift from the cytoplasmic compartment 
(normal epithelium) to the nucleus (dysplasia) (22). 
  It remains difficult to allot a well-defined role to galectins in 
regulation phenomena that proceed in cholesteatomas, and this 
is due to two reasons. The first one is related to galectins own 
properties. Galectins are implied in a very large amount of bio-
logical phenomena - sometimes opposites. They do not depend 
only on the type of cell in which they take place, but also on their 
localization (nuclear, cytoplasmic or extracellular) (8, 10, 12), 
which makes there interpretation difficult. The second reason is 
due to the small size of our samples. 
  To conclude, the data reported in this study suggest that on 
the basis of a lesser marked galectin-3 in cholesteatomas epithe-
lium compared with an external auditory canal skin that an im-
mature keratinocytes population is at the origin of these lesions 
and that galectin-3 and galectin-7 play a part in the capacity as 
apoptosis modulators. If our study does not establish a differ-
ence in the galectin expressions of congenital and acquired cho-
lesteatomas, it constitutes however an additional argument in 
favor of the “undifferentiated” origin of keratinocytes in choles-
teatomas. 
  To establish more precisely the role of galectins and the fac-
tors influencing their expression in cholesteatomas, and to de-
termine possible biological differences between congenital and 
acquired specimens, a broader study with a larger sample group 
would be necessary.
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